INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK CITY, NY / ACCESS Newswire / November 6, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On October 29, 2026, Alnylam reported its financial results for the third quarter ended September 30, 2026. Among other items, the Company reported slowing demand for one of its transthyretin-mediated amyloidosis treatments, Amvuttra, which accounts for 87.5% of Alnylam's product sales. Alnylam announced U.S. total transthyretin demand growth of $81 million, compared to $129 million for the preceding quarter.

On this news, Alnylam's stock price fell $58.40, or 25.13%, to close at $174.00 on October 29, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP